Altria Scientists Present at CPDD 2025

Each year, the College on Problems of Drug Dependence (CPDD) Annual Scientific Meeting brings together researchers, clinicians, policymakers, and industry leaders to share the latest science on substance use, addiction, and treatment. This year, several Altria scientists contributed to the conversation by highlighting our research in support of tobacco harm reduction.

Dr. Hong shared science supporting the PMTA application for the Ploom® System, a heated tobacco product that Horizon Innovations, a joint venture between Philip Morris USA and JTI Holding, plans to commercialize upon FDA authorization. Dr. Hong walked the audience through the harm reduction opportunity of the Ploom^® System in the U.S. by sharing data from an abuse liability assessment, including nicotine exposure and subjective effects measures.

In a poster session, Dr. Vergara highlighted nicotine pharmacokinetics and subjective effects data from NJOY ACE, an FDA-authorized e-vapor product. The findings support NJOY ACE as a potentially suitable alternative to combustible cigarettes.

Additionally, Dr. Salehi and Gabriel presented a poster detailing a study that used a published human physiologically based pharmacokinetic (PBPK) model to quantify nicotine uptake in the buccal cavity and transfer to the GI tract from various nicotine pouch products.